Table 2.
Influence of MCAO on PPT-B and NK3 mRNA levels in cerebral cortex and caudate-putamen
| PPT-B | NK3 | ||||
|---|---|---|---|---|---|
| Sham | MCAO | Sham | MCAO | ||
| Cg, Fr | 6 hr | 56.7 ± 12.9 | 53.6 ± 12.1 | 110.8 ± 21.7 | 106.4 ± 9.6 |
| (ipsi) | 2 d | 48.6 ± 11.7 | 139.7 ± 68.7* (+187%) | 121.3 ± 15.4 | 18.3 ± 21.22-160 (−84%) |
| 7 d | 43.7 ± 6.1 | 107.0 ± 40.3* (+144%) | 89.1 ± 17.6 | 63.0 ± 14.0* (−29%) | |
| Cg, Fr | 6 hr | 48.6 ± 16.4 | 47.4 ± 12.2 | 106.7 ± 15.2 | 101.5 ± 15.9 |
| (contra) | 2 d | 44.0 ± 12.6 | 65.3 ± 31.1 | 104.4 ± 13.1 | 102.7 ± 21.8 |
| 7 d | 52.9 ± 10.3 | 53.9 ± 22.0 | 83.5 ± 12.6 | 70.3 ± 12.3 | |
| FL, Par, I | 6 hr | 54.5 ± 16.0 | 56.3 ± 18.1 | 95.6 ± 24.5 | 79.7 ± 13.3 |
| (contra) | 2 d | 48.8 ± 12.5 | 76.3 ± 23.3* (+56%) | 86.1 ± 17.2 | 105.1 ± 24.9 |
| 7 d | 65.7 ± 22.4 | 69.5 ± 26.6 | 66.6 ± 11.7 | 61.4 ± 11.4 | |
| CPu | 6 hr | 22.4 ± 2.1 | 12.5 ± 3.32-160 (−44%) | n.d. | n.d. |
| (ipsi) | 2 d | 22.0 ± 4.1 | 53.5 ± 11.02-160 (+143%) | n.d. | n.d. |
| 7 d | 19.2 ± 7.1 | 51.1 ± 19.72-160 (+166%) | n.d. | n.d. | |
| CPu | 6 hr | 22.5 ± 3.6 | 22.3 ± 5.8 | n.d. | n.d. |
| (contra) | 2 d | 23.9 ± 3.0 | 32.4 ± 4.3* (+35%) | n.d. | n.d. |
| 7 d | 25.5 ± 7.3 | 24.8 ± 9.9 | n.d. | n.d. | |
Values are mean mRNA levels expressed in nCi/gm ± SD (6 animals per group). Bold values indicate the percent increase or decrease after MCAO as compared with sham treatment set as 100%. Areas of the cortex: Cg, cingulate; FL, forelimb; Fr, frontal; I, insular; Par, parietal. CPu, Caudate-putamen; contra, contralateral; ipsi, ipsilateral.
*
p < 0.05;
F2-160: p < 0.01 versus the sham-operated group; Student's ttest.